Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve P Lee

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Radiation Research|October 10, 2017
Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapyHsing-Lung Chao, Shao-Cheng Liu, Chih-Cheng Tsao, et al.
Head & Neck|January 1, 2019
Treatment outcomes with whole-field versus split-field intensity-modulated radiotherapy for patients with nasopharyngeal carcinomaChun-Shu Lin, Yuan-Wu Chen, Shao-Cheng Liu, et al.
Journal of X-Ray Science and Technology|February 4, 2017
Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancerChun-You Chen, Liang-Ming Lee, Hsiao-Wei Yu, et al.
JCO Oncology Practice|March 18, 2021
Palliative Radiotherapy Within the Veterans Health Administration: Barriers to Referral and Timeliness of TreatmentRuchika Gutt, Sheetal Malhotra, Michael P Hagan, et al.
Cancer Research|December 4, 2002
Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinomaChen-Lung Lin, Wei-Feng Lo, Tzong-Hsien Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|April 8, 2015
Near Real-Time Assessment of Anatomic and Dosimetric Variations for Head and Neck Radiation Therapy via Graphics Processing Unit-based Dose Deformation FrameworkX Sharon Qi, Anand Santhanam, John Neylon, et al.
BMC Cancer|April 3, 2019
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseNeil R Parikh, Claudia Huiza, Jill S Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated RadiationJonathan Tward, Lauren Lenz, Darl D Flake, et al.
European Urology Oncology|June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed TherapyJesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Radiation Research|October 10, 2017
Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapyHsing-Lung Chao, Shao-Cheng Liu, Chih-Cheng Tsao, et al.
Head & Neck|January 1, 2019
Treatment outcomes with whole-field versus split-field intensity-modulated radiotherapy for patients with nasopharyngeal carcinomaChun-Shu Lin, Yuan-Wu Chen, Shao-Cheng Liu, et al.
Journal of X-Ray Science and Technology|February 4, 2017
Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancerChun-You Chen, Liang-Ming Lee, Hsiao-Wei Yu, et al.
JCO Oncology Practice|March 18, 2021
Palliative Radiotherapy Within the Veterans Health Administration: Barriers to Referral and Timeliness of TreatmentRuchika Gutt, Sheetal Malhotra, Michael P Hagan, et al.
Cancer Research|December 4, 2002
Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinomaChen-Lung Lin, Wei-Feng Lo, Tzong-Hsien Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|April 8, 2015
Near Real-Time Assessment of Anatomic and Dosimetric Variations for Head and Neck Radiation Therapy via Graphics Processing Unit-based Dose Deformation FrameworkX Sharon Qi, Anand Santhanam, John Neylon, et al.
BMC Cancer|April 3, 2019
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseNeil R Parikh, Claudia Huiza, Jill S Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|October 5, 2021
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated RadiationJonathan Tward, Lauren Lenz, Darl D Flake, et al.
European Urology Oncology|June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed TherapyJesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III TrialsAndrew J Armstrong, Vinnie Y T Liu, Ramprasaath R Selvaraju, et al.
Pageof 7